Kevin Accola, MD, spoke to Cardiovascular Business about new 10-year data on the performance of surgical valves featuring Resilia tissue. The findings are good news for Edwards Lifesciences, which also includes the tissue on many of its TAVR devices.
Becoming a father seems to make a man less likely to die young. What’s more, when a father passes away within the first five years of his child’s life, the cause is usually non-natural and thus preventable.
Researchers tracked real-world data from 600 TAVR patients, following each one for approximately five years. Survival rates were similar for men and women early on, but then women started experiencing better outcomes after three years.
Howard Herrmann, MD, MSCAI, Hospital of the University of Pennsylvania, and lead invesigator for the SMART trial, explains details on the 2-year data comparing the Evolut vs. Sapien 3 for TAVR in small annulus patients.
Researchers in Toronto used MRI scans to measure the brain as it heals after injury. They found damage persists for a year after athletes are medically cleared to return to the field.
While the policy of President Donald Trump is to axe research on transgender issues and DEI, scientists who spoke to the Boston Globe said their work does not run up against those restrictions.
Two separate groups have published new research comparing early AVR with clinical surveillance for the treatment of asymptomatic severe aortic stenosis. Overall, the two groups found, early treatment was associated with multiple benefits—and no added risk of harm.
Researchers involved in its development are hopeful that the scanner could eventually lead to improved outcomes in cancer patients who require surgery to remove malignant tissue.
